Literature DB >> 32715599

Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau.

Mitchel A Kling1,2, Dayan B Goodenowe3, Vijitha Senanayake3, Siamak MahmoudianDehkordi4, Matthias Arnold4,5, Tyler J Massaro6, Rebecca Baillie7, Xianlin Han8, Yuk-Yee Leung9, Andrew J Saykin10, Kwangsik Nho10, Alexandra Kueider-Paisley4, Jessica D Tenenbaum11, Li-San Wang9, Leslie M Shaw9, John Q Trojanowski9, Rima F Kaddurah-Daouk4,12,13.   

Abstract

INTRODUCTION: Altered lipid metabolism is implicated in Alzheimer's disease (AD), but the mechanisms remain obscure. Aging-related declines in circulating plasmalogens containing omega-3 fatty acids may increase AD risk by reducing plasmalogen availability.
METHODS: We measured four ethanolamine plasmalogens (PlsEtns) and four closely related phosphatidylethanolamines (PtdEtns) from the Alzheimer's Disease Neuroimaging Initiative (ADNI; n = 1547 serum) and University of Pennsylvania (UPenn; n = 112 plasma) cohorts, and derived indices reflecting PlsEtn and PtdEtn metabolism: PL-PX (PlsEtns), PL/PE (PlsEtn/PtdEtn ratios), and PBV (plasmalogen biosynthesis value; a composite index). We tested associations with baseline diagnosis, cognition, and cerebrospinal fluid (CSF) AD biomarkers.
RESULTS: Results revealed statistically significant negative relationships in ADNI between AD versus CN with PL-PX (P = 0.007) and PBV (P = 0.005), late mild cognitive impairment (LMCI) versus cognitively normal (CN) with PL-PX (P = 2.89 × 10-5 ) and PBV (P = 1.99 × 10-4 ), and AD versus LMCI with PL/PE (P = 1.85 × 10-4 ). In the UPenn cohort, AD versus CN diagnosis associated negatively with PL/PE (P = 0.0191) and PBV (P = 0.0296). In ADNI, cognition was negatively associated with plasmalogen indices, including Alzheimer's Disease Assessment Scale 13-item cognitive subscale (ADAS-Cog13; PL-PX: P = 3.24 × 10-6 ; PBV: P = 6.92 × 10-5 ) and Mini-Mental State Examination (MMSE; PL-PX: P = 1.28 × 10-9 ; PBV: P = 6.50 × 10-9 ). In the UPenn cohort, there was a trend toward a similar relationship of MMSE with PL/PE (P = 0.0949). In ADNI, CSF total-tau was negatively associated with PL-PX (P = 5.55 × 10-6 ) and PBV (P = 7.77 × 10-6 ). Additionally, CSF t-tau/Aβ1-42 ratio was negatively associated with these same indices (PL-PX, P = 2.73 × 10-6 ; PBV, P = 4.39 × 10-6 ). In the UPenn cohort, PL/PE was negatively associated with CSF total-tau (P = 0.031) and t-tau/Aβ1-42 (P = 0.021). CSF Aβ1-42 was not significantly associated with any of these indices in either cohort. DISCUSSION: These data extend previous studies by showing an association of decreased plasmalogen indices with AD, mild cognitive impairment (MCI), cognition, and CSF tau. Future studies are needed to better define mechanistic relationships, and to test the effects of interventions designed to replete serum plasmalogens.
© 2020 the Alzheimer's Association.

Entities:  

Keywords:  case-control study; dementia; lipidomics; mass spectrometry; metabolomics; mild cognitive impairment; phosphatidylethanolamines; plasmenylethanolamines

Year:  2020        PMID: 32715599      PMCID: PMC8152932          DOI: 10.1002/alz.12110

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  43 in total

1.  Plasma phospholipids identify antecedent memory impairment in older adults.

Authors:  Mark Mapstone; Amrita K Cheema; Massimo S Fiandaca; Xiaogang Zhong; Timothy R Mhyre; Linda H MacArthur; William J Hall; Susan G Fisher; Derick R Peterson; James M Haley; Michael D Nazar; Steven A Rich; Dan J Berlau; Carrie B Peltz; Ming T Tan; Claudia H Kawas; Howard J Federoff
Journal:  Nat Med       Date:  2014-03-09       Impact factor: 53.440

2.  Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain.

Authors:  L Ginsberg; S Rafique; J H Xuereb; S I Rapoport; N L Gershfeld
Journal:  Brain Res       Date:  1995-11-06       Impact factor: 3.252

Review 3.  Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis.

Authors:  Alain Koyama; Olivia I Okereke; Ting Yang; Deborah Blacker; Dennis J Selkoe; Francine Grodstein
Journal:  Arch Neurol       Date:  2012-07

4.  Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study.

Authors:  Ernst J Schaefer; Vanina Bongard; Alexa S Beiser; Stefania Lamon-Fava; Sander J Robins; Rhoda Au; Katherine L Tucker; David J Kyle; Peter W F Wilson; Philip A Wolf
Journal:  Arch Neurol       Date:  2006-11

5.  Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease.

Authors:  Z Guan; Y Wang; N J Cairns; P L Lantos; G Dallner; P J Sindelar
Journal:  J Neuropathol Exp Neurol       Date:  1999-07       Impact factor: 3.685

Review 6.  Dyslipidemia and the risk of Alzheimer's disease.

Authors:  Christiane Reitz
Journal:  Curr Atheroscler Rep       Date:  2013-03       Impact factor: 5.113

7.  2016 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2016-04       Impact factor: 21.566

8.  Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease.

Authors:  Giuseppe Astarita; Kwang-Mook Jung; Nicole C Berchtold; Vinh Q Nguyen; Daniel L Gillen; Elizabeth Head; Carl W Cotman; Daniele Piomelli
Journal:  PLoS One       Date:  2010-09-08       Impact factor: 3.240

9.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins.

Authors:  Sandip Ray; Markus Britschgi; Charles Herbert; Yoshiko Takeda-Uchimura; Adam Boxer; Kaj Blennow; Leah F Friedman; Douglas R Galasko; Marek Jutel; Anna Karydas; Jeffrey A Kaye; Jerzy Leszek; Bruce L Miller; Lennart Minthon; Joseph F Quinn; Gil D Rabinovici; William H Robinson; Marwan N Sabbagh; Yuen T So; D Larry Sparks; Massimo Tabaton; Jared Tinklenberg; Jerome A Yesavage; Robert Tibshirani; Tony Wyss-Coray
Journal:  Nat Med       Date:  2007-10-14       Impact factor: 53.440

10.  Plasma proteins predict conversion to dementia from prodromal disease.

Authors:  Abdul Hye; Joanna Riddoch-Contreras; Alison L Baird; Nicholas J Ashton; Chantal Bazenet; Rufina Leung; Eric Westman; Andrew Simmons; Richard Dobson; Martina Sattlecker; Michelle Lupton; Katie Lunnon; Aoife Keohane; Malcolm Ward; Ian Pike; Hans Dieter Zucht; Danielle Pepin; Wei Zheng; Alan Tunnicliffe; Jill Richardson; Serge Gauthier; Hilkka Soininen; Iwona Kłoszewska; Patrizia Mecocci; Magda Tsolaki; Bruno Vellas; Simon Lovestone
Journal:  Alzheimers Dement       Date:  2014-07-08       Impact factor: 21.566

View more
  7 in total

Review 1.  Tricky Isomers-The Evolution of Analytical Strategies to Characterize Plasmalogens and Plasmanyl Ether Lipids.

Authors:  Jakob Koch; Katrin Watschinger; Ernst R Werner; Markus A Keller
Journal:  Front Cell Dev Biol       Date:  2022-04-27

Review 2.  Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease.

Authors:  Dallas P Veitch; Michael W Weiner; Paul S Aisen; Laurel A Beckett; Charles DeCarli; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Susan M Landau; John C Morris; Ozioma Okonkwo; Richard J Perrin; Ronald C Petersen; Monica Rivera-Mindt; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; Duygu Tosun; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2021-09-28       Impact factor: 16.655

3.  Lipidomic Analysis of Postmortem Prefrontal Cortex Phospholipids Reveals Changes in Choline Plasmalogen Containing Docosahexaenoic Acid and Stearic Acid Between Cases With and Without Alzheimer's Disease.

Authors:  Yurika Otoki; Shunji Kato; Kiyotaka Nakagawa; Danielle J Harvey; Lee-Way Jin; Britany N Dugger; Ameer Y Taha
Journal:  Neuromolecular Med       Date:  2021-01-21       Impact factor: 4.103

4.  Deep mining of oxysterols and cholestenoic acids in human plasma and cerebrospinal fluid: Quantification using isotope dilution mass spectrometry.

Authors:  Eylan Yutuc; Alison L Dickson; Manuela Pacciarini; Lauren Griffiths; Paul R S Baker; Lisa Connell; Anders Öhman; Lars Forsgren; Miles Trupp; Sílvia Vilarinho; Youssef Khalil; Peter T Clayton; Sinan Sari; Buket Dalgic; Philip Höflinger; Ludger Schöls; William J Griffiths; Yuqin Wang
Journal:  Anal Chim Acta       Date:  2021-02-04       Impact factor: 6.558

5.  Human Gray and White Matter Metabolomics to Differentiate APOE and Stage Dependent Changes in Alzheimer's Disease.

Authors:  Tyler C Hammond; Xin Xing; Lucy M Yanckello; Arnold Stromberg; Ya-Hsuan Chang; Peter T Nelson; Ai-Ling Lin
Journal:  J Cell Immunol       Date:  2021

6.  Vitamin B12 Attenuates Changes in Phospholipid Levels Related to Oxidative Stress in SH-SY5Y Cells.

Authors:  Elena Leoni Theiss; Lea Victoria Griebsch; Anna Andrea Lauer; Daniel Janitschke; Vincent Konrad Johannes Erhardt; Elodie Christiane Haas; Konstantin Nicolas Kuppler; Juliane Radermacher; Oliver Walzer; Dorothea Portius; Heike Sabine Grimm; Tobias Hartmann; Marcus Otto Walter Grimm
Journal:  Cells       Date:  2022-08-18       Impact factor: 7.666

7.  Targeted Plasmalogen Supplementation: Effects on Blood Plasmalogens, Oxidative Stress Biomarkers, Cognition, and Mobility in Cognitively Impaired Persons.

Authors:  Dayan B Goodenowe; Jonathan Haroon; Mitchel A Kling; Margaret Zielinski; Kennedy Mahdavi; Barshen Habelhah; Leah Shtilkind; Sheldon Jordan
Journal:  Front Cell Dev Biol       Date:  2022-07-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.